	US 11,834,473 B2
	Engineered O-glycosylation in recombinant polypeptides and uses thereof
Adam Tibbles, Cambridge (GB); Monika Papworth, Cambridge (GB); Daniel Higazi, Cambridge (GB); Emmanuel Rossy, Cambridge (GB); Katarzyna Anna Kozakowska, Cambridge (GB); and Thomas Vincent Murray, Cambridge (GB)
Assigned to MedImmune Limited, Cambridge (GB)
Appl. No. 16/956,006
Filed by MedImmune Limited, Cambridge (GB)
PCT Filed Dec. 20, 2018, PCT No. PCT/EP2018/086385 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/122234, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/608,812, filed on Dec. 21, 2017.
Prior Publication US 2020/0317724 A1, Oct. 8, 2020
Int. Cl. A61K 47/62 (2017.01); C07K 1/107 (2006.01); C07K 9/00 (2006.01); C07K 14/605 (2006.01); C12P 21/00 (2006.01); A61K 38/00 (2006.01)

CPC C07K 1/1077 (2013.01) [A61K 47/62 (2017.08); C07K 9/001 (2013.01); C07K 14/605 (2013.01); C12P 21/005 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)]

4 Claims

1. A polypeptide comprising an O-linked glycosylation sequence, wherein the O-linked glycosylation sequence comprises a sequence selected from SEQ ID Nos: 2-14, and wherein the O-linked glycosylation sequence is covalently bound to an O-glycan.